Our Mediclose team recently had the pleasure of visiting our incredible partner, Assut Europe, in beautiful Rome.

Corporis Medical completed an all equity financing round, including the conversion of existing convertible loans. The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors, including Brightlands Ventures Partners and LIOF.

Today marks the successful launch of the OP-Zuid project STIM-00953, “Laprixa, the Intra-operative Predictor of Wound Healing Capacity”!

Corporis Medical CSO Dr. Alexander Veenhof has successfully completed the first in vivo test for our latest innovation, “the miniaturized Laprixa probe”.

This past Tuesday, the Corporis Medical team attended TEFAF Maastricht, courtesy of Brightlands.

After extensive review of Corporis Medical’s 510(k) pre-market submission, the FDA has granted its approval for the Mediclose System to enter the US market!

Led by our CSO and founder Alexander Veenhof, Corporis Medical’s Mediclose System has been validated in patients in a multicenter First-in-Human clinical investigation. With this, we have demonstrated that the Mediclose System is safe for use and reduces port closure time significantly, compared to manual closure.

EIT Health awards Corporis Medical's “Objective surgical wound healing indicator” with the Quality Label.